Delivery Order SPE2DB22D3501-SPE2DB25FWP12
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $18,788.88 to AmerisourceBergen Drug Corp for the supply of Vyvanse 20 mg capsules (100-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order valued at $1,832.02 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg, with a completion date of July 24, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a ceiling value of $4,284.71. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025. The award was competitively procured with no set-aside designation, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order valued at $1,339.21 to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (100-count packages) on July 21, 2025, with an ultimate completion date of July 22, 2025. The contract employs firm fixed pricing and is not set aside for any specific business category. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal healthcare vendor specializing in...
- The Defense Logistics Agency awarded a $7,598.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units). This is a non-set-aside competitive award with performance completion scheduled for July 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location. This delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a $1,269.13 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWP12Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,238.84 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being performed at the contractor's Conshohocken, Pennsylvania location. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, functions as a critical vendor within the Defense Health Agency's medical supply chain. Through its DLA IDC, the company supplies an extensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems globally, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Vyvanse, a prescription medication commonly used in the treatment of attention deficit hyperactivity disorder, exemplifies the routine fulfillment of pharmaceutical needs under this overarching contract vehicle that enables flexible and responsive medical supply procurement across the Department of Defense enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/24/25 |